A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2-locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling

被引：0
|
作者：
LeVee, Alexis Ann
Egelston, Colt A.
Yost, Susan Elaine
Frankel, Paul Henry
Lee, Keehoon
Ruel, Christopher
Schmolze, Daniel
Lee, Peter P.
Yeon, Christina Haeyoung
Yuan, Yuan
Waisman, James Ross
Pal, Sumanta Kumar
Mortimer, Joanne E.
机构：
[1] City Hope Comprehens Canc Ctr, Duarte, CA USA
[2] Translat Genom Res Inst TGen North, Flagstaff, AZ USA
[3] Cedars Sinai Med Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [32] Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2-breast cancer in Germany: Interim results of the INGE-B phase II study
    Welt, A.
    Welslau, M. K.
    Lueftner, D.
    Deryal, M.
    Liersch, R.
    Sahlmann, J.
    Houet, L.
    Vannier, C.
    Marschner, N.
    Potthoff, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC).
    Anders, Carey K.
    Le Rhun, Emilie
    Bachelot, Thomas Denis
    Yardley, Denise A.
    Awada, Ahmad
    Conte, Pier Franco
    Kabos, Peter
    Bear, Melissa
    Yang, Zhengyu
    Chen, Yanyun
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2-Metastatic Breast Cancer
    Jeselsohn, Rinath
    Fu, Jingxin
    Ren, Yue
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy
    Abdou, Yara
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Ko, Naomi
    Liu, Yuan
    Burstein, Harold
    DeMeo, Michelle
    Tolaney, Sara
    Mayer, Erica
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer: final results from the POLARIS trial
    Tripathy, Debu
    Blum, Joanne L.
    Karuturi, Meghan S.
    Mccune, Steven
    Kurian, Sobha
    Moezi, Mehdi
    Anderson, Daniel
    Gauthier, Eric
    Zhang, Zhe
    Montelongo, Monica Z.
    Wang, Yao
    Rocque, Gabrielle B.
    ONCOLOGIST, 2024,
  • [36] Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2-metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study
    Raghavendra, Akshara Singareeka
    Ha, Min Jin
    Kettner, Nicole M.
    Damodaran, Senthil
    Layman, Rachel
    Hunt, Kelly K.
    Shen, Yu
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2022, 82 (04)
  • [37] Real-World Comparison of Overall Survival in Female Patients with HR+/HER2-Metastatic breast cancer receiving endocrine therapy, endocrine therapy plus palbociclib, or chemotherapy
    Rizwan, U.
    Hussain, R.
    Kanagala, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 54 - 55
  • [38] PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
    Martinez-Janez, Noelia
    Ezquerra, Meritxell Bellet
    Henao, Fernando
    Manso, Luis
    Anton, Antonio
    Zamora, Pilar
    Murillo, Serafin Morales
    Tolosa, Pablo
    Andres, Raquel
    Calvo, Lourdes
    Galve, Elena
    Lopez, Rafael
    de la Pena, Francisco Ayala
    Lopez-Tarruella, Sara
    Boronat, Laia
    Martos, Tamara
    Chacon, J. Ignacio
    Alvarez, Isabel
    de la Haba-Rodriguez, Juan
    Anton, Fernando Moreno
    CANCER RESEARCH, 2023, 83 (05)
  • [39] Treatment sequencing in HR+/HER2-locally advanced or metastatic breast cancer: A real-world retrospective study in France, Germany, Italy and Spain
    Lewis, K.
    Kurosky, S.
    Last, M.
    Mitra, D.
    Lambert, A.
    Mahtani, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S375 - S376
  • [40] Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2-early breast cancer
    Mayer, Erica L.
    Fesl, Christian
    Dueck, Amylou
    Gnant, Michael
    DeMichele, Angela
    CANCER RESEARCH, 2021, 81 (04)
12345